We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biogen’s Gene Therapy for Retinal Disease Misses Mark in Phase 2/3 Trial
Biogen’s Gene Therapy for Retinal Disease Misses Mark in Phase 2/3 Trial
Biogen’s experimental gene therapy, cotoretigene toliparvovec, failed to show efficacy in a phase 2/3 study of patients suffering from a rare, inherited retinal disease.